{
    "clinical_study": {
        "@rank": "80506", 
        "arm_group": [
            {
                "arm_group_label": "Exforge\u00ae 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)", 
                "arm_group_type": "Active Comparator", 
                "description": "Exforge\u00ae 10/160"
            }, 
            {
                "arm_group_label": "G-0081 (Amlodipine orotate 10mg / Valsratan 160mg)", 
                "arm_group_type": "Experimental", 
                "description": "G-0081"
            }
        ], 
        "brief_summary": {
            "textblock": "Study Design : randomized, open label, single-dose, 2-way cross-over design\n\n      Phase : Phase I"
        }, 
        "brief_title": "A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge\u00ae and G-0081 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Male Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy male volunteers between the ages of 20 to 50 years old within the range of\n             \u00b120% of IBW(Ideal Body Weight)\n\n          -  having neither congenital/chronic diseases nor pathological symptoms/findings as\n             results of medical examination\n\n          -  doctor determines to be suitable as subjects within 4 weeks ago before administration\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity(or history of hypersensitivity) to amlodipine and valsartan\n\n          -  Active Liver Diseases or exceed 1.5 times the normal range of AST, ALT\n\n          -  Gastrointestinal diseases or surgeries that affect absorption of drug\n\n          -  Excessive drinking(exceed 30g/week) and excessive caffeine(exceed 250mg/day)\n\n          -  Smoking over 10 cigarettes per day"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776047", 
            "org_study_id": "G-0081_BA_I"
        }, 
        "intervention": [
            {
                "arm_group_label": "Exforge\u00ae 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)", 
                "intervention_name": "Exforge\u00ae", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "G-0081 (Amlodipine orotate 10mg / Valsratan 160mg)", 
                "intervention_name": "G-0081", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Amlodipine, valsartan drug combination"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 23, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge\u00ae and G-0081 in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Head of Clinical Development, Clinical Trials Center Severance Hospital", 
            "last_name": "K S Park, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "AUClast, Cmax", 
            "safety_issue": "No", 
            "time_frame": "Blood gathering point : 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h, 72h, 96h, 144h, 192h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776047"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "AUCinf = AUClast + Clast/\u03bbz\n%AUCextra = [ (AUCinf - AUClast) / AUCinf ] \u00d7100\nt1/2 = 0.693/\u03bbz", 
            "measure": "AUCinf, Tmax, t1/2, % AUCextra", 
            "safety_issue": "No", 
            "time_frame": "Blood gathering point : 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h, 72h, 96h, 144h, 192h"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}